Marzena Zboch

Donanemab in Early Symptomatic Alzheimer Disease

John R. Sims, Jennifer A. Zimmer, Cynthia Evans et al. · JAMA · 2023 · 2.6K citations · Full text

Medicine, Neurology, Neuroscience +17

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

Willemijn J. Jansen, Olin Janssen, Betty M. Tijms et al. · JAMA Neurology · 2022 · 288 citations · Full text

Medicine, Neurology, Neuroscience +17

Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease

Edmond Teng, Paul T. Manser, Karen Pickthorn et al. · JAMA Neurology · 2022 · 191 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia

Willemijn J. Jansen, Rik Ossenkoppele, Betty M. Tijms et al. · JAMA Psychiatry · 2017 · 148 citations · Full text

Medicine, Neurology, Neuroscience +17

Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet

Cecília Monteiro, Balázs István Tóth, Flávia Brunstein et al. · Neurology · 2023 · 108 citations · Full text

Life Sciences, Neurology, Neuroscience +17